Minerva Completes Development Of Once-daily Dose Formulation Of MIN-101

(RTTNews) - Minerva Neurosciences Inc. (NERV) announced the completion of development and final selection of a once-daily dose formulation of MIN-101, an antagonist on 5-HT2A and Sigma2 receptors for the treatment of schizophrenia. The new formulation will be used in the company's planned Phase 2b clinical trial in schizophrenia, scheduled to begin recruiting in the first half of 2015.

The company believes that the new once-daily formulation will be able to maintain plasma levels of MIN-101 over the course of one day while reducing BFB-520 levels and increasing levels of BFB-999 associated with sleep improvements due to its affinity to 5-HT2A and histaminergic H1 receptors.